IPO registrations (S-1, F-1) · Registrants
Ainos, Inc.
- SEC CIK
- 1014763 · filings on EDGAR ↗
- Former names
- AMARILLO BIOSCIENCES INC (1996–2021)
- Registration
- Form S-1, first filed 2008-04-24, last 2024-04-08; 5 initial registrations, 9 amendments
- Outcome
- Final prospectus filed 2022-08-10; declared effective 2008-06-12
- Industry (SIC)
- Computer Peripheral Equipment, NEC 3577
- Incorporated in
- TX
- Business address
- 3050 POST OAK BLVD,, SUITE 510-T80, Houston, TX 77056
- EIN
- 75-1974352
- Ticker
- AIMD, AIMDW (Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Ainos, Inc. on the corporate pages
Offering terms
- Final price
- $4.25 per share (424B4 filed 2022-08-10)
- Shares sold
- 780,000
- Gross proceeds
- $3,315,000 before underwriting discounts and any over-allotment option
- Listing
- OTC under the symbol AIMD
- Lead underwriters
- Maxim Group
- Syndicate
- Brookline Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Ainos, Inc. EXACT (CIK (EXACT))
- SEC filer: Ainos, Inc. EXACT (CIK (EXACT))
Filings 23
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2008-04-24 | S-1 | S-1 (registration) | AMARILLO BIOSCIENCES INC | 0001144204-08-024038 ↗ |
| 2008-05-21 | S-1/A | S-1/A (amendment) | AMARILLO BIOSCIENCES INC | 0001144204-08-031333 ↗ |
| 2008-06-06 | S-1/A | S-1/A (amendment) | AMARILLO BIOSCIENCES INC | 0001144204-08-034027 ↗ |
| 2008-06-12 | EFFECT | EFFECT (declared effective) | AMARILLO BIOSCIENCES INC | 9999999995-08-001882 ↗ |
| 2009-12-23 | S-1 | S-1 (registration) | AMARILLO BIOSCIENCES INC | 0001269678-09-000233 ↗ |
| 2010-02-05 | S-1/A | S-1/A (amendment) | AMARILLO BIOSCIENCES INC | 0001269678-10-000016 ↗ |
| 2011-02-28 | S-1/A | S-1/A (amendment) | AMARILLO BIOSCIENCES INC | 0001269678-11-000190 ↗ |
| 2011-03-28 | EFFECT | EFFECT (declared effective) | AMARILLO BIOSCIENCES INC | 9999999995-11-000773 ↗ |
| 2011-06-21 | EFFECT | EFFECT (declared effective) | AMARILLO BIOSCIENCES INC | 9999999995-11-001910 ↗ |
| 2022-04-28 | S-1 | S-1 (registration) | Ainos, Inc. | 0001654954-22-005505 ↗ |
| 2022-07-08 | S-1/A | S-1/A (amendment) | Ainos, Inc. | 0001654954-22-009450 ↗ |
| 2022-07-25 | S-1/A | S-1/A (amendment) | Ainos, Inc. | 0001654954-22-010003 ↗ |
| 2022-07-27 | S-1/A | S-1/A (amendment) | Ainos, Inc. | 0001654954-22-010097 ↗ |
| 2022-08-02 | S-1/A | S-1/A (amendment) | Ainos, Inc. | 0001654954-22-010419 ↗ |
| 2022-08-08 | EFFECT | EFFECT (declared effective) | Ainos, Inc. | 9999999995-22-002291 ↗ |
| 2022-08-10 | 424B4 | 424B4 (final prospectus) | Ainos, Inc. | 0001654954-22-010988 ↗ |
| 2023-12-08 | S-1 | S-1 (registration) | Ainos, Inc. | 0001654954-23-015299 ↗ |
| 2023-12-15 | S-1/A | S-1/A (amendment) | Ainos, Inc. | 0001654954-23-015642 ↗ |
| 2023-12-18 | EFFECT | EFFECT (declared effective) | Ainos, Inc. | 9999999995-23-003681 ↗ |
| 2024-04-08 | S-1 | S-1 (registration) | Ainos, Inc. | 0001493152-24-013774 ↗ |
| 2024-04-16 | EFFECT | EFFECT (declared effective) | Ainos, Inc. | 9999999995-24-000993 ↗ |
| 2024-06-11 | EFFECT | EFFECT (declared effective) | Ainos, Inc. | 9999999995-24-001815 ↗ |
| 2024-12-31 | EFFECT | EFFECT (declared effective) | Ainos, Inc. | 9999999995-25-000019 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-02 | S-1/A | registration statement | $0.25 | - | - | 0 | primary document; price line | document ↗ | ||
| 2022-08-10 | 424B4 | final prospectus | $4.25 | 780,000 | $3,315,000 | OTC AIMD | 2 | primary document; price table, shares headline, proceeds table, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| CHEN STEPHEN T | Director; Director,Officer; Director,Officer,TenPercentOwner; Other | President, CEO, and Chairman; President, CEO & Chairman; President,CEO & Chairman; President,CEO,Chairman; President, Chairman & CEO; President,Chairman & CEO; President,Chairman,CEO,CFO | 242 | 2006–2022 | |
| CUMMINS JOSEPH M | Director,Officer; Officer | Chairman, President and CEO; Chair of Brd, President &CEO; Chmn of the BOD, Pres, CEO; Chmn of the BOD, Pres., CEO; Chnm of the BOD, Pres, CEO; PRES,CEO,CHAIRMAN OF THE BOARD; Pres CEO Chmn of Board; Pres-CEO-Chmn of Board; PRES, CEO & CHMN OF THE BOARD; PRES, CEO, CHMN OF THE BOARD; PRES,CEO, CHMN OF THE BOARD; PRES,CEO,CHMN OF THE BOARD; PRES, CEO, & CHMN OF THE BOD; PRES, CEO, CHMN OF THE BOD | 54 | 2006–2011 | |
| MOORE DENNIS DEAN | Director | 8 | 2006–2012 | ||
| COY GARY WAYNE | Director,Officer; Officer; Other | VP and CFO; VP AND CFO | 17 | 2006–2009 | |
| Cummins Martin Joseph | Director,Officer; Officer | VP, Clinical & Regulatory Affa; VP Clinical & Regulatory Affai; VP,CLINICAL & REGULATORY AFFAI | 7 | 2007–2010 | |
| THOMAS R ULIE | Director | 2 | 2007 | ||
| D'ALONZO THOMAS W | Director | 5 | 2007–2010 | ||
| PAGE JAMES A | Director | 4 | 2007–2010 | ||
| MUELLER PETER ROBERT | Officer | COO AND DIRECTOR OF RESEARCH; COO & DIRECTOR OF RESEARCH | 8 | 2008–2009 | |
| Cohen Bernard H | Officer | Vice President; Vice President-Administration; Vice President & CFO; VP, CFO | 10 | 2010–2019 | |
| Paul Tibbits | Director; Director,TenPercentOwner | 35 | 2011–2012 | ||
| TIBBITS MARIAN | Director | 1 | 2011 | ||
| AINOS INC | TenPercentOwner | 8 | 2021–2023 | ||
| chang wen-han | Director | 9 | 2021–2025 | ||
| chiang yao-chung | Director | 16 | 2021–2026 | ||
| chiu hsiu-chen | Director | 2 | 2021 | ||
| lee ting-chuan | Director | 18 | 2021–2026 | ||
| tsai chung-jung | Director | 18 | 2021–2026 | ||
| tsai chung-yi | Director; Director,Officer | CEO, PRESIDENT, CHAIRMAN | 8 | 2021–2025 | |
| tsai chun-hsien | Director,Officer | CEO, PRESIDENT, CHAIRMAN; Chairman, CEO, CFO; CHIEF EXECUTIVE OFFICER | 16 | 2021–2026 | |
| LIN LAWRENCE K | Officer; Other | E.V.P. OF OPERATIONS | 4 | 2021–2024 | |
| Wu Hui-Lan | Officer | Chief Financial Officer | 8 | 2022–2023 | |
| WEI PAO-SHENG | Director | 8 | 2022–2025 | ||
| Sung Meng Lin | Officer | Chief Financial Officer | 3 | 2023–2024 | |
| Lee Hsin-Liang Christopher | Officer | CFO; Chief Financial Officer | 5 | 2024–2025 | |
| ASE Technology Holding Co., Ltd. | TenPercentOwner | 1 | 2024 | ||
| ASE Test, Inc. | TenPercentOwner | 4 | 2024–2026 | ||
| Taiwan Carbon Nano Technology Corp | TenPercentOwner | 10 | 2024–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-05-03 | Ainos, Inc. | Biotechnology | $20,000,000 | $20,000,000 | 0 | 1 |
| 2017-12-19 | AMARILLO BIOSCIENCES INC | Biotechnology | $30,000,000 | $721,033 | 10 | 3 |
| 2016-05-06 | AMARILLO BIOSCIENCES INC | Biotechnology | $2,812,500 | $476,479 | 4 | 3 |
| 2016-04-07 | AMARILLO BIOSCIENCES INC | Biotechnology | $1,000,000 | $600,000 | 1 | 1 |
| 2015-08-03 | AMARILLO BIOSCIENCES INC | Biotechnology | Indefinite | $37,500 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Ainos, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Ainos, Inc. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.